How nicotine pouches are causing a rise in poisoning cases among young children and what parents can do to prevent it ...

The FDA has approved the interferon gamma-blocking antibody emapalumab -lzsg (Gamifant) for the treatment of macrophage activation syndrome (MAS) in known or suspected Still disease.

The FDA has approved Gamifant as the first-ever treatment for macrophage activation syndrome in Still’s disease for adults and children who have an inadequate response or intolerance to ...

In a major step forward for HIV prevention, the FDA has approved lenacapavir—branded as Yeztugo the first HIV prevention shot that only needs to be taken twice a year.

It’s expected to cost more than $28,000 per year in the U.S., but most folks won't pay full price FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been ...

Key TakeawaysKey Takeaways A new HIV shot taken twice a year was nearly 100% effective in trials Global funding cuts could limit access to the drug, though It’s expected to cost more than ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections. Originally approved in 2012 as a treatment for people with HIV that no longer responded to ...

Sold under the name Yeztugo, the shot has shown remarkable effectiveness in clinical trials.

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.

The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The twice-yearly formulation has the brand name Yeztugo.

It's the world's first twice-yearly shot and was shown in trials to be 96% effective at preventing HIV. Advocates call it a gamechanger.

The Food and Drug Administration approved the first injectable HIV prevention medication, which could be a massive step forward in ending the long-term epidemic.